Effects of the COVID-19 pandemic on medication adherence: In the case of antiseizure medications, A scoping review

Menon, Sonia; Sander, Josemir W.

doi:10.1016/j.seizure.2021.10.009

Cited by 17 publications

(17 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the pandemic continues, it remains essential to provide counseling on risk mitigation, particularly to people with epilepsy who have an even greater need for self‐management during this time. 18 , 34 …”

Section: Discussionmentioning

confidence: 99%

“…Such discrepancies underscore the need for better country‐contextualized understanding of how COVID‐19 is affecting people with epilepsy and the tailored mechanisms required to mitigate adverse impacts as the pandemic continues to evolve. 34 …”

Section: Discussionmentioning

confidence: 99%

“…Stress and worry causing forgetfulness was cited as the main contributor in the US; changes to routine, particularly the ability to access healthcare services and prescriptions for medications, was the most important factor in the UK; and difficulty obtaining prescriptions and altered or canceled appointments was the principal reason in Brazil. Such discrepancies underscore the need for better country‐contextualized understanding of how COVID‐19 is affecting people with epilepsy and the tailored mechanisms required to mitigate adverse impacts as the pandemic continues to evolve 34 …”

Section: Discussionmentioning

confidence: 99%

“…41% of those people with epilepsy on whom caregivers reported had intellectual disability and 33% had memory difficulties, requiring caregivers to advocate on their behalf. As the pandemic continues, it remains essential to provide counseling on risk mitigation, particularly to people with epilepsy who have an even greater need for self‐management during this time 18,34 …”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Impact of theCOVID‐19 pandemic on people with epilepsy: Findings from theUSarm of theCOV‐Estudy

et al. 2022

Self Cite

View full text Add to dashboard Cite

Objectives As part of the COVID‐19 and Epilepsy (COV‐E) global study, we aimed to understand the impact of COVID‐19 on the medical care and well‐being of people with epilepsy (PWE) in the United States, based on their perspectives and those of their caregivers. Methods Separate surveys designed for PWE and their caregivers were circulated from April 2020 to July 2021; modifications in March 2021 included a question about COVID‐19 vaccination status. Results We received 788 responses, 71% from PWE (n = 559) and 29% (n = 229) from caregivers of persons with epilepsy. A third (n = 308) of respondents reported a change in their health or in the health of the person they care for. Twenty‐seven percent (n = 210) reported issues related to worsening mental health. Of respondents taking ASMs (n = 769), 10% (n = 78) reported difficulty taking medications on time, mostly due to stress causing forgetfulness. Less than half of respondents received counseling on mental health and stress. Less than half of the PWE reported having discussions with their healthcare providers about sleep, ASMs, and potential side effects, while a larger proportion of caregivers (81%) reported having had discussions with their healthcare providers on the same topics. More PWE and caregivers reported that COVID‐19‐related measures caused adverse impact on their health in the post‐vaccine period than during the pre‐vaccine period, citing mental health issues as the primary reason. Significance Our findings indicate that the impact of the COVID‐19 pandemic in the US on PWE is multifaceted. Apart from the increased risk of poor COVID‐19 outcomes, the pandemic has also had negative effects on mental health and self‐management. Healthcare providers must be vigilant for increased emotional distress in PWE during the pandemic and consider the importance of effective counseling to diminish risks related to exacerbated treatment gaps.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of theCOVID‐19 pandemic on people with epilepsy: Findings from theUSarm of theCOV‐Estudy

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“… 34 In conditions such as seizures and epilepsy, where drug therapy is the main form of control, adherence to medication was poor. 35 Collectively, this builds a picture of non-adherence to pharmacotherapy that may be intentional or unintentional. This study aims to investigate prescription reimbursement data of CVD medicines as a proxy measure for rates of adherence and access to essential medicines.…”

Section: Introductionmentioning

confidence: 99%

Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England’s prescription data during the COVID-19 pandemic (January 2019 to October 2020)

Barrett

Hodgkinson

2022

Therapeutic Advances in Cardiovascular Disease

View full text Add to dashboard Cite

Background: Management of high blood pressure (BP) typically requires adherence to medication regimes. However, it is known that the COVID-19 pandemic both interrupted access to some routine prescriptions and changed some patient health behaviours. Aim: This study, therefore, retrospectively investigated prescription reimbursement of cardiovascular (CVD) medicines as a proxy measure for patient adherence and access to medicines during the pandemic. Methods: A cohort study of all primary care patients in England prescribed CVD medicines. The exposure was to the global pandemic. Prescriptions were compared before and after the pandemic’s onset. Statistical variation was the outcome of interest. Results: Descriptive statistics show changes to monthly prescriptions, with wide confidence intervals indicating varying underlying practice. Analysis of variance reveals statistically significant differences for bendroflumethiazide, potassium-sparing diuretics, nicorandil, ezetimibe, ivabradine, ranolazine, colesevelam and midodrine. After the pandemic began (March–October 2020), negative parameters are observed for ACE inhibitors, beta-blockers, calcium channel blockers, statins, antiplatelet, antithrombotics, ARBs, loop diuretics, doxazosin, bendroflumethiazide, nitrates and indapamide, indicating decelerating monthly prescription items (statistically significant declines of calcium channel blockers, antithrombotic, adrenoreceptor blockers and diuretics) of CVD medicines within the general population. Many data points are not statistically significant, but fluctuations remain clinically important for the large population of patients taking these medications. Conclusion: A concerning decline in uptake of CVD therapies for chronic heart disease was observed. Accessible screening and treatment alongside financial relief on prescription levies are needed. A video abstract is (4 min 51 s) available: https://bit.ly/39gvEHi

show abstract

Analysis of the evolocumab (Repatha®) patient support program for patients with cardiovascular disease in Colombia

García-Peña,

Pineda-Posada,

Páez-Canro

et al. 2023

Clínica e Investigación en Arteriosclerosis (English Edition)

View full text Add to dashboard Cite

Effects of the COVID-19 pandemic on medication adherence: In the case of antiseizure medications, A scoping review

Cited by 17 publications

References 43 publications

Impact of theCOVID‐19 pandemic on people with epilepsy: Findings from theUSarm of theCOV‐Estudy

Impact of theCOVID‐19 pandemic on people with epilepsy: Findings from theUSarm of theCOV‐Estudy

Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England’s prescription data during the COVID-19 pandemic (January 2019 to October 2020)

Analysis of the evolocumab (Repatha®) patient support program for patients with cardiovascular disease in Colombia

Contact Info

Product

Resources

About